bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
172 hedge funds and large institutions have $581M invested in bluebird bio in 2021 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 21 increasing their positions, 119 reducing their positions, and 49 closing their positions.
1.82% less ownership
Funds ownership: 5.97% → 4.15% (-1.8%)
12% less funds holding
Funds holding: 196 → 172 (-24)
28% less call options, than puts
Call options by funds: $4.38M | Put options by funds: $6.11M
42% less capital invested
Capital invested by funds: $996M → $581M (-$415M)
45% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 49
82% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 119
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$19.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$8.44M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$6.14M |
| 4 |
Rafferty Asset Management
New York
|
+$3.77M |
| 5 |
Citigroup
New York
|
+$3.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$53.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$43.8M |
| 3 |
BlackRock
New York
|
-$35.4M |
| 4 |
SC
Sessa Capital
New York
|
-$22.7M |
| 5 |
AC
Armistice Capital
New York
|
-$17.3M |
BLUE Hedge Fund Activity: Q4 2021 in Review
172 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q4 2021, worth a combined $581M — down 42% from $996M a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of BLUE and 27 opened new positions — a net loss of 22 holders — while 119 trimmed existing stakes and 21 added.
The largest buyer was First Trust Advisors, adding an estimated $19.5M. The largest seller was Wellington Management Group, cutting an estimated $53.6M.
- 172 institutional investors held bluebird bio (BLUE) as of Q4 2021, down from 196 in Q3 2021.
- Funds reported $581M of bluebird bio stock for Q4 2021, down 42% quarter-over-quarter.
- 27 funds opened new bluebird bio positions in Q4 2021 and 49 closed out, a net change of -22 holders.
- The largest bluebird bio buyer in Q4 2021 was First Trust Advisors, an estimated $19.5M added.
- The largest bluebird bio seller in Q4 2021 was Wellington Management Group, an estimated $53.6M sold.
Based on aggregated 13F filings for Q4 2021.